Renee Yan on Muck Rack

Renee Yan

Verified
Colleyville
As seen in: Community Impact Newspaper, Chron, Flipboard, KTRK-TV (Houston, TX), D Magazine, Newswise, NewsBreak, The Beaumont Enterprise, Laredo Morning Times, The Plainview Herald, The Shorthorn and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Renee

Contact Renee, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

State’s investment in cancer research has helped draw top talent to UTSW

|
By Renee Yan Verified
| utsouthwestern.edu
Joshua Gruber, M.D., Ph.D., (left) Assistant Professor of Internal Medicine, and Matteo Ligorio, M.D., Ph.D., Assistant Professor of Surgery, both joined UT Southwestern after being awarded First-Time, Tenure-Track Faculty Member grants from the state-funded Cancer Prevention and Research Institute of Texas. DALLAS – Dec.
Open in Who Shared View Duplicates (2) Issue with article?

A MEG powerhouse: How UTSW is pushing the limits of brain research, care

|
By Renee Yan Verified
| utsouthwestern.edu
DALLAS – Aug. 21, 2025 – Most days, neurologist Sasha Alick-Lindstrom, M.D., M.P.H., FAAN, FACNS, FAES, can be found staring at rows of brain signals on multiple computer screens, inspecting the squiggly lines for any irregularities or spikes of electrical activity.
Open in Who Shared Issue with article?

Time in a bottle: How UTSW paved the way for a breakthrough brain cancer drug

|
By Renee Yan Verified, Rick Press
| Newswise
For neuro-oncologist Elizabeth Maher, M.D., Ph.D., the pictures are worth a thousand words. In the lobby of UT Southwestern’s Cancer Care Outpatient Building, two of Dr. Maher’s patients are smiling and posing with their first doses of a newly approved drug that slows the growth of their brain tumors. The breakthrough medication, called vorasidenib, was approved by the Food and Drug Administration (FDA) in August 2024.
Open in Who Shared Issue with article?
See all 1,472 licensed articles (1,485 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified